FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775293762> ?p ?o ?g. }

• W2775293762 endingPage "282" @default.
• W2775293762 startingPage "272" @default.
• W2775293762 abstract "Despite recent progress in the development of novel approaches to treat cancer, traditional antineoplastic drugs, such as cisplatin, remain a mainstay of regimens targeting solid tumors. Use of cisplatin is limited by acute kidney injury, which occurs in approximately 30% of patients. Current clinical measures, such as serum creatinine and estimated glomerular filtration rate, are inadequate in their ability to detect acute kidney injury, particularly when there is only a moderate degree of injury. Thus, there is an urgent need for improved diagnostic biomarkers to predict nephrotoxicity. There is also interest by the U.S. Food and Drug Administration to validate and implement new biomarkers to identify clinical and subclinical acute kidney injury in patients during the drug approval process. This minireview provides an overview of the current literature regarding the utility of urinary proteins (albumin, beta-2-microglobulin, N-acetyl-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and cystatin C) as biomarkers for cisplatin-induced AKI. Many of the well-studied urinary proteins (KIM-1, NGAL, B2M, albumin) as well as emerging biomarkers (calbindin, monocyte chemotactic protein-1, and trefoil factor 3) display distinct patterns of time-dependent excretion after cisplatin administration. Implementation of these biomarker proteins in the oncology clinic has been hampered by a lack of validation studies. To address these issues, large head-to-head studies are needed to fully characterize time-dependent responses and establish accurate cutoff values and ranges, particularly in cancer patients. Impact statement There is growing interest in using urinary protein biomarkers to detect acute kidney injury in oncology patients prescribed the nephrotoxic anticancer drug cisplatin. We aim to synthesize and organize the existing literature on biomarkers examined clinically in patients receiving cisplatin-containing chemotherapy regimens. This minireview highlights several proteins (kidney injury molecule-1, beta-2-microglobulin, neutrophil gelatinase-associated lipocalin, calbindin, monocyte chemotactic protein-1, trefoil factor 3) with the greatest promise for detecting cisplatin-induced acute kidney injury in humans. A comprehensive review of the existing literature may aid in the design of larger studies needed to implement the clinical use of these urinary proteins as biomarkers of kidney injury." @default.
• W2775293762 created "2017-12-22" @default.
• W2775293762 creator A5008201175 @default.
• W2775293762 creator A5045125159 @default.
• W2775293762 creator A5085602255 @default.
• W2775293762 date "2017-12-12" @default.
• W2775293762 modified "2023-10-02" @default.
• W2775293762 title "Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy" @default.
• W2775293762 cites W1523210369 @default.
• W2775293762 cites W1554013484 @default.
• W2775293762 cites W1594491177 @default.
• W2775293762 cites W1919610996 @default.
• W2775293762 cites W1964501614 @default.
• W2775293762 cites W1966142961 @default.
• W2775293762 cites W1969848985 @default.
• W2775293762 cites W1970622564 @default.
• W2775293762 cites W1971492805 @default.
• W2775293762 cites W1982768697 @default.
• W2775293762 cites W1989152348 @default.
• W2775293762 cites W1991944268 @default.
• W2775293762 cites W1992988573 @default.
• W2775293762 cites W1996945731 @default.
• W2775293762 cites W2003418600 @default.
• W2775293762 cites W2006611167 @default.
• W2775293762 cites W2012267668 @default.
• W2775293762 cites W2013093345 @default.
• W2775293762 cites W2013275926 @default.
• W2775293762 cites W2014243721 @default.
• W2775293762 cites W2014478530 @default.
• W2775293762 cites W2017611639 @default.
• W2775293762 cites W2022983144 @default.
• W2775293762 cites W2026216861 @default.
• W2775293762 cites W2028361448 @default.
• W2775293762 cites W2029242992 @default.
• W2775293762 cites W2033968408 @default.
• W2775293762 cites W2034002939 @default.
• W2775293762 cites W2037880961 @default.
• W2775293762 cites W2043036855 @default.
• W2775293762 cites W2044567696 @default.
• W2775293762 cites W2045421375 @default.
• W2775293762 cites W2045592841 @default.
• W2775293762 cites W2047497410 @default.
• W2775293762 cites W2048848435 @default.
• W2775293762 cites W2053943923 @default.
• W2775293762 cites W2058117893 @default.
• W2775293762 cites W2063107464 @default.
• W2775293762 cites W2065810709 @default.
• W2775293762 cites W2068979787 @default.
• W2775293762 cites W2078209296 @default.
• W2775293762 cites W2078956388 @default.
• W2775293762 cites W2083157400 @default.
• W2775293762 cites W2086098076 @default.
• W2775293762 cites W2088415931 @default.
• W2775293762 cites W2089752042 @default.
• W2775293762 cites W2094066576 @default.
• W2775293762 cites W2098650139 @default.
• W2775293762 cites W2098983938 @default.
• W2775293762 cites W2099623158 @default.
• W2775293762 cites W2111239148 @default.
• W2775293762 cites W2118732356 @default.
• W2775293762 cites W2119022117 @default.
• W2775293762 cites W2119194499 @default.
• W2775293762 cites W2125690161 @default.
• W2775293762 cites W2129761622 @default.
• W2775293762 cites W2136066292 @default.
• W2775293762 cites W2136819926 @default.
• W2775293762 cites W2141455657 @default.
• W2775293762 cites W2145136986 @default.
• W2775293762 cites W2151685988 @default.
• W2775293762 cites W2151765833 @default.
• W2775293762 cites W2152467472 @default.
• W2775293762 cites W2154450105 @default.
• W2775293762 cites W2162349483 @default.
• W2775293762 cites W2165923646 @default.
• W2775293762 cites W2171984881 @default.
• W2775293762 cites W2172052007 @default.
• W2775293762 cites W2316471728 @default.
• W2775293762 cites W2328094192 @default.
• W2775293762 cites W2334731873 @default.
• W2775293762 cites W2337424574 @default.
• W2775293762 cites W2342452849 @default.
• W2775293762 cites W2399168373 @default.
• W2775293762 cites W2442687535 @default.
• W2775293762 cites W2561042291 @default.
• W2775293762 cites W2563393230 @default.
• W2775293762 cites W2569373054 @default.
• W2775293762 cites W2592377167 @default.
• W2775293762 cites W2597104405 @default.
• W2775293762 cites W2726384217 @default.
• W2775293762 cites W3106649452 @default.
• W2775293762 cites W4238336108 @default.
• W2775293762 cites W4360754409 @default.
• W2775293762 cites W927594411 @default.
• W2775293762 cites W2091787202 @default.
• W2775293762 doi "https://doi.org/10.1177/1535370217745302" @default.
• W2775293762 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813872" @default.
• W2775293762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29231123" @default.
• W2775293762 hasPublicationYear "2017" @default.

• next